Hospital incidence, in-hospital mortality and medical costs of pneumococcal disease in Spain (2008–2017): a retrospective multicentre study

References

• O'Brien KL, Wolfson LJ, Watt JP, Hib and Pneumococcal Global Burden of Disease Study Team, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374(9693):893–902.
   PubMed Web of Science ®Google Scholar
• de Egea V, Muñoz P, Valerio M, et al. Characteristics and outcome of Streptococcus pneumoniae endocarditis in the XXI century: a systematic review of 111 cases (2000–2013). Medicine. 2015;94(39):e1562.
   PubMed Web of Science ®Google Scholar
• Waisman DC, Tyrrell GJ, Kellner JD, et al. Pneumococcal peritonitis: still with us and likely to increase in importance. Can J Infect Dis Med Microbiol. 2010;21(1):e23–e27.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases. In: Hamborsky J, Kroger A, Wolfe S, editors. 13th ed. Washington D.C. Public Health Foundation; 2015.
   Google Scholar
• European Centre for Disease Prevention and Control. Annual epidemiological report 2017–invasive pneumococcal disease. ECDC; 2019 [cited 2020 May 8]. Available from: https://www.ecdc.europa.eu/en/publications-data/invasive-pneumococcal-disease-annual-epidemiological-report-2017.
   Google Scholar
• Centers for Disease Control and Prevention. Pneumococcal disease. CDC; 2017 [cited 2020 May 8]. Available from: https://www.cdc.gov/pneumococcal/surveillance.html.
   Google Scholar
• GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459–1544.
   PubMed Web of Science ®Google Scholar
• Gil-Prieto R, Pascual-Garcia R, Walter S, et al. Risk of hospitalization due to pneumococcal disease in adults in Spain. The CORIENNE study. Hum Vaccin Immunother. 2016;12(7):1900–1905.
   PubMed Web of Science ®Google Scholar
• Soneji S, Metlay J. Mortality reductions for older adults differ by race/ethnicity and gender since the introduction of adult and pediatric pneumococcal vaccines. Public Health Rep. 2011;126(2):259–269.
   PubMed Web of Science ®Google Scholar
• Ludwig G, Garcia-Garcia S, Lanaspa M, and Catalan Study Group of Invasive Pneumococcal Disease, et al. Serotype and clonal distribution dynamics of invasive Pneumococcal strains after PCV13 introduction (2011–2016): Surveillance data from 23 sites in Catalonia. PLOS One. 2020;15(2):e0228612.
   PubMed Web of Science ®Google Scholar
• Vanderkooi OG, Scheifele DW, Girgenti D, Canadian PCV13 Study Group, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada. Pediatr Infect Dis J. 2012;31(1):72–77.
   PubMed Web of Science ®Google Scholar
• Domínguez Á, Ciruela P, Hernández S, et al. Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7–59 months. A matched case-control study. PLOS One. 2017;12(8):e0183191.
   PubMed Web of Science ®Google Scholar
• Horácio AN, Silva-Costa C, Lopes JP, et al. Serotype 3 remains the leading cause of invasive pneumococcal disease in adults in Portugal (2012–2014) despite continued reductions in other 13-valent conjugate vaccine serotypes. Front Microbiol. 2016;7:1616.
   PubMed Web of Science ®Google Scholar
• Càmara J, Marimón JM, Cercenado E, et al. Decrease of invasive pneumococcal disease (IPD) in adults after introduction of pneumococcal 13-valent conjugate vaccine in Spain. PLOS One. 2017;12(4):e0175224.
   PubMed Web of Science ®Google Scholar
• Katkade VB, Sanders KN, Zou KH. Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making. J Multidiscip Healthc. 2018;11:295–304.
   PubMed Web of Science ®Google Scholar
• Justo N, Espinoza MA, Ratto B, et al. Real-world evidence in healthcare decision making: global trends and case studies from Latin America. Value Health. 2019;22(6):739–749.
   PubMed Web of Science ®Google Scholar
• Spanish Ministry of Health. Hospital discharge records in the National Health System. Spanish Ministry of Health; 2019 [cited 2020 Feb 10]. Available from: https://www.mscbs.gob.es/estadEstudios/sanidadDatos/home.html.
   Google Scholar
• Centers for Disease Control and Prevention (CDC). International Classification of Diseases, Ninth Revision, clinical modification (ICD-9-CM). CDC; 2015 [cited 2020 May 11]. Available from: https://www.cdc.gov/nchs/icd/icd9cm.htm.
   Google Scholar
• Centers for Disease Control and Prevention (CDC). International Classification of Diseases, Tenth Revision, clinical modification (ICD-10-CM). CDC; 2020 [cited 2020 May 11]. Available from: https://www.cdc.gov/nchs/icd/icd10cm.htm.
   Google Scholar
• Law 14/2007, 3rd July, on biomedical research (BOE, 4 July 2007). Rev Derecho Genoma Hum. 2007;1(26):283–325.
   PubMedGoogle Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–619.
   PubMed Web of Science ®Google Scholar
• Sundararajan V, Quan H, Halfon P, International Methodology Consortium for Coded Health Information (IMECCHI), et al. Cross-national comparative performance of three versions of the ICD-10 Charlson index. Med Care. 2007;45(12):1210–1215.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Annual epidemiological report 2014 – invasive pneumococcal disease. ECDC; 2016 [cited 2020 May 8]. Available from: https://www.ecdc.europa.eu/en/publications-data/invasive-pneumococcal-disease-annual-epidemiological-report-2016-2014-data.
   Google Scholar
• Vila-Corcoles A, Ochoa-Gondar O, Vila-Rovira A, et al. Incidence and risk of pneumococcal pneumonia in adults with distinct underlying medical conditions: a population-based study. Lung. 2020;198(3):481–489.
   PubMed Web of Science ®Google Scholar
• Ludwig E, Bonanni P, Rohde G, et al. The remaining challenges of pneumococcal disease in adults. Eur Respir Rev. 2012;21(123):57–65.
   PubMedGoogle Scholar
• Song JY, Choi JY, Lee JS, et al. Clinical and economic burden of invasive pneumococcal disease in adults: a multicenter hospital-based study. BMC Infect Dis. 2013;13(1):202.
   PubMed Web of Science ®Google Scholar
• Huang SS, Johnson KM, Ray GT, et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine. 2011;29(18):3398–3412.
   PubMed Web of Science ®Google Scholar
• Spanish Ministry of Health. Sistema de Cuentas de Salud 2018: Principales resultados. Spanish Ministry of Health; 2020 [cited 2020 Oct 7]. Available from: https://www.mscbs.gob.es/estadEstudios/estadisticas/sisInfSanSNS/pdf/SCSprincipalesResultados.pdf.
   Google Scholar